Skip to main content
. 2022 Apr 1;6(7):2207–2218. doi: 10.1182/bloodadvances.2021005487

Table 2.

Treatment response for the ITT population (all randomly assigned patients)

Response Arm A (azacitidine + durvalumab) (n = 42) Arm B (azacitidine) (n = 42) P
No. (%) 95% CI No. (%) 95% CI
ORR (CR + PR + mCR + HI) 26 (61.9) 47.22-76.59 20 (47.6) 32.51-62.72 .1838
CR 3 (7.1) 0.00-14.93 4 (9.5) 0.65-18.40
mCR 15 (35.7) 21.22-50.21 8 (19.0) 7.17-30.92
PR 0 0
HI only 8 (19.0) 7.17-30.92 8 (19.0) 7.17-30.92
SD 6 (14.3) 3 (7.1)

ITT, intent to treat; PR, partial remission; SD, stable disease.